Investment Banking
Axios turned to William Blair’s Biopharma investment banking group and its “Quarterly Rx” report for insights in a recent story on IPO and investing activity in the sector.
“The big picture: Big Pharma has been active this year, with the value of upfront partnership payments to biotech companies in 2025 surpassing the last four years, per a William Blair report,” the article said.
Stay up-to-date with the latest William Blair news and insights
William Blair acted as a joint active bookrunner on the $314.0 million initial public offering for BillionToOne, Inc. (Nasdaq: BLLN), a high-growth, commercial-stage precision diagnostics company transforming healthcare through its proprietary single-molecule next-generation sequencing (smNGS) platform.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
